BioCentury | Nov 22, 2017
Clinical News
Researchers use RWE to reproduce trial results
...randomized clinical trial that supported a supplemental indication of cardiovascular risk reduction for hypertension drug telmisartan...
...received telmisartan or comparator ramipril. The claims data were available at the time FDA approved telmisartan's...
...almost an identical hazard ratio (HR=0.99) as ONTARGET (HR=1.01) on the primary endpoint, which compared telmisartan...
...received telmisartan or comparator ramipril. The claims data were available at the time FDA approved telmisartan's...
...almost an identical hazard ratio (HR=0.99) as ONTARGET (HR=1.01) on the primary endpoint, which compared telmisartan...